- Home
- ATYR vs MNOV Comparison
ATYR vs MNOV Comparison
Compare ATYR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | MNOV |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 72.7M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | ATYR | MNOV |
|---|---|---|
| Price | $0.75 | $1.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $4.20 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 985.5K | 63.8K |
| Earning Date | 03-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $0.64 | $1.13 |
| 52 Week High | $7.29 | $1.96 |
Technical Indicators
Market Signals| Indicator | ATYR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 44.39 |
| Support Level | $0.67 | $1.22 |
| Resistance Level | $0.85 | $1.40 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.23 | 17.64 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.